Sana Biotechnology (SANA)
(Delayed Data from NSDQ)
$5.87 USD
-0.28 (-4.55%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $5.87 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
SANA 5.87 -0.28(-4.55%)
Will SANA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SANA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SANA
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice
SANA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?
Other News for SANA
JMP Securities healthcare analysts hold an analyst/industry conference call
GSK and Flagship Pioneering partner to discover novel medicines and vaccines
Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World
JMP Securities healthcare analysts hold an analyst/industry conference call
Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class